TABLE 2.
Univariable and multivariable OR and 95% CI for a positive COVID-19 test result among solid organ transplant patients who were tested
| Variable | Univariable OR (95% CI) | Multivariable OR (95% CI) |
|---|---|---|
| Sex | ||
| Male | Ref | – |
| Female | 0.95 (0.86-1.04) | |
| Age | ||
| 18–45 y | Ref | Ref |
| 45–65 y | 0.88 (0.78-0.98) | 0.99 (0.98-1.00) |
| >65 y | 0.74 (0.65-0.85) | 0.97 (0.96-0.99)a |
| Race | ||
| White | Ref | Ref |
| Black or African American | 2.31 (2.07-2.59) | 1.06 (1.05-1.07)a |
| Hispanic or Latino | 2.41 (2.1-2.78) | 1.07 (1.06-1.09)a |
| Other/unknown | 1.89 (1.61-2.23) | 1.04 (1.03-1.06)a |
| Organ type | ||
| Kidney | 1.92 (1.72-2.13) | 1.02 (1.00-1.03) |
| Liver | 0.62 (0.54-0.70) | 0.97 (0.96-0.98)a |
| Lung | 0.46 (0.39-0.55) | 0.97 (0.95-0.99)a |
| Other/unknown | 0.93 (0.81-1.07) | – |
| Comorbidities | ||
| CKD | 2.17 (1.95-2.42) | 1.01 (1.00-1.02) |
| Hypertension | 3.18 (2.77-3.64) | 1.05 (1.04-1.06)a |
| Diabetes | 1.75 (1.59 -1.93) | 1.02 (1.01-1.03)a |
| Asthma | 1.16 (1.02-1.31) | 1.01 (1.00-1.02) |
| Cancer | 1.33 (1.19-1.46) | 1.01 (1.00-1.02) |
| Coronary artery disease | 1.70 (1.54-1.88) | 1.01 (1.00-1.03) |
| Congestive heart failure | 1.32 (1.19-1.46) | 0.99 (0.98-1.00) |
| Peripheral vascular disease | 1.65 (1.48-1.83) | 1.02 (1.01-1.03)a |
| Liver disease | 0.95 (0.86-1.06) | – |
| Obesity | 1.13 (1.00-1.27) | 1.00 (0.99-1.02) |
| Obesity missing | 1.22 (1.09-1.36) | 1.01 (1.00-1.02) |
| Immunosuppression | ||
| Prednisone | 1.31 (1.18-1.45) | 0.99 (0.98-1.01) |
| Tacrolimus | 1.60 (1.44-1.78) | 1.03 (1.02-1.04)a |
| Cyclosporine | 0.97 (0.82-1.15) | – |
| MMF | 1.52 (1.37-1.68) | 1.01 (1.00-1.02) |
| ATG induction | 1.55 (1.32-1.81) | 1.00 (0.98-1.02) |
| Basiliximab induction | 0.53 (0.41-0.68) | 0.95 (0.93-0.97)a |
a Statistically significant at a P < 0.05.
ATG, antithymocyte globulin; CI, confidence interval; CKD, chronic kidney disease; COVID-19, coronavirus disease 2019; MMF, mycophenolate mofetil; OR, odds ratio.